You are here

ADENOSINE THERAPEUTICS, LLC

Company Information
Address
310 FOURTH STREET NE SUITE 201
CHARLOTTESVILLE, VA 22902
United States



Information

UEI: N/A

# of Employees: N/A


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. NOVEL ADENOSINE A2A AGONISTS IN RENAL TISSUE PROTECTION

    Amount: $0.00

    DESCRIPTION (provided by applicant): The development of new treatments for the effective reduction of renal injury associated with acute renal failure and kidney transplantation will have a great impa ...

    SBIRPhase I2002Department of Health and Human Services National Institutes of Health
  2. NOVEL ADENOSINE A2A AGONISTS IN RENAL TISSUE PROTECTION

    Amount: $818,282.00

    DESCRIPTION (provided by applicant): The development of new treatments for the effective reduction of renal injury associated with acute renal failure and kidney transplantation will have a great impa ...

    SBIRPhase II2002Department of Health and Human Services National Institutes of Health
  3. A2A ADENOSINE AGONIST ADJUNCT FOR SYSTEMIC ANTHRAX

    Amount: $198,360.00

    DESCRIPTION (provided by applicant): This project develops A2A adenosine receptor (A2AAR) agonists as adjuncts to antibiotics for the treatment of anthrax septicemia. It responds to the urgent need fo ...

    STTRPhase I2002Department of Health and Human Services National Institutes of Health
  4. A2A ADENOSINE AGONISTS LIMIT DAMAGE FROM INFECTION

    Amount: $0.00

    epsis syndrome is the 11th leading cause of death in the United States ( about 900,000 new cases per year) with a mortality of about 35 percent. The need for adjunctive therapies is urgent. In Phase I ...

    STTRPhase I2002Department of Health and Human Services National Institutes of Health
  5. A2A ADENOSINE AGONISTS LIMIT DAMAGE FROM INFECTION

    Amount: $943,553.00

    epsis syndrome is the 11th leading cause of death in the United States ( about 900,000 new cases per year) with a mortality of about 35 percent. The need for adjunctive therapies is urgent. In Phase I ...

    STTRPhase II2002Department of Health and Human Services National Institutes of Health
  6. A2A ADENOSINE AGONISTS AS NEUROPROTECTANTS

    Amount: $137,289.00

    DESCRIPTION (provided by applicant): The central goal of this research is to develop a new drug to prevent spinal cord reperfusion injury secondary to aortic clamping that occurs fr ...

    SBIRPhase I2002Department of Health and Human Services National Institutes of Health
  7. A2A ADENOSINE AGONISTS AS NEUROPROTECTANTS

    Amount: $928,760.00

    DESCRIPTION (provided by applicant): The central goal of this research is to develop a new drug to prevent spinal cord reperfusion injury secondary to aortic clamping that occurs fr ...

    SBIRPhase II2002Department of Health and Human Services National Institutes of Health
  8. Antagonists of A2B Receptors Improve Insulin Sensitivity

    Amount: $100,000.00

    DESCRIPTION (Scanned from the Applicant's Abstract): Blockade of A2B adenosine receptors (A2BARs) increases insulin sensitivity in insulin resistant obese Zucker rats by an effect on sk ...

    SBIRPhase I2001Department of Health and Human Services National Institutes of Health
  9. ANTAGONIST OF A2B ADENOSINE RECEPTORS FOR ASTHMA

    Amount: $100,000.00

    DESCRIPTION: (Adapted from the Investigator's Abstract): Adenosine administered as an aerosol to asthmatics causes bronchoconstriction, while in non-asthmatics adenosine causes bronchodilati ...

    SBIRPhase I2001Department of Health and Human Services National Institutes of Health
  10. N/A

    Amount: $100,000.00

    N/A

    STTRPhase I2000Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government